1. A compound represented by general formula (I):
a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2\u2014.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar is a group represented by a formula:
or a pyridyl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar is a group represented by a formula:
in which R15 is a lower alkyl group; and
A is a bond.
4. A compound represented by general formula (II):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a di(lower alkyl)amino group, a carboxy group, or a lower alkoxycarbonyl group;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12;
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group; and
R15 is a lower alkyl group.
5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein
R9 is \u2014COR10, or \u2014OCH2COR10; and
R10 is a hydroxy group or a lower alkoxy group.
6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein at least one of R2 and R3 is a hydrogen atom.
7. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are a hydrogen atom.
8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
each of R4 and R5 is independently a hydrogen atom or a lower alkyl group; and R6 is a lower alkyl group.
9. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4 is a hydrogen atom; and
each of R5 and R6 is independently a lower alkyl group.
10. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4, R5 and R6 are a hydrogen atom; and
R8 is a halogen atom, a lower alkyl group, a lower alkoxy group, or a di(lower alkyl)amino group.
11. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4, R5 and R6 are a hydrogen atom; and
R8 is a lower alkyl group.
12. The compound according to claim 1, a lower alkyl ester thereof, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid;
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-carboxylic acid;
(4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-yloxy)acetic acid;
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-carboxylic acid;
(4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-yloxy)acetic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-2-methylbiphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-3,4-dicarboxylic acid;
3-(N,N-dimethylamino)-4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-biphenyl-4-carboxylic acid;
3-ethoxy-4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)propylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid; and
4\u2032-{2-(R)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)propylaminoethoxy}-3-isopropyl-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid.
13. A pharmaceutical composition which comprises, as an active ingredient, a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2\u2014, and a pharmaceutically acceptable carrier.
14. A pharmaceutical combination comprising (A) a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2; and
(B) at least one member selected from the group consisting of an antiobesity agent, an antidiabetic agent, a hypolipidemic agent and a therapeutic agent for urinary dysfunctions other than a \u03b23-adrenoceptor agonist.
15. A method for treating obesity, diabetes mellitus, hyperlipidemia, depression, urinary dysfunctions, diseases caused by biliary calculus or biliary tract hypermotility, or diseases caused by intestinal hypermotility, which comprises administering an effective amount of a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower aikoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A remote displaying apparatus comprising:
a main body including a display configured to display an image wirelessly transmitted from an image pickup apparatus, and a connection section for attaching the main body to an attachment object; and
a belt configured to fix the main body and a user arm.
2. The remote displaying apparatus according to claim 1, wherein the main body further includes a record operation button to transmit an instruction of a start or an end of recording to the image pickup apparatus.
3. The remote displaying apparatus according to claim 2, wherein the main body further includes a first face, the display and the record operation button are on the first face, and the connection section is at a second face of the main body other than the first face.
4. The remote displaying apparatus according to claim 1, wherein the main body further includes a selection button used to select an item from a menu displayed on the display.
5. The remote displaying apparatus according to claim 1, wherein the main body further includes a notification section which lights up when the image pickup apparatus is in a recording state.
6. The remote displaying apparatus according to claim 1, wherein the main body further includes:
a record operation button to transmit an instruction of a start or an end of recording to the image pickup apparatus; and
a notification section to notify when the image pickup apparatus is in a recording state by pressing the record operation button.
7. The remote displaying apparatus according to claim 1, wherein the main body further includes a terminal configured to charge a battery of the remote displaying apparatus by linking an external device.
8. The remote displaying apparatus according to claim 7, wherein the terminal is covered.
9. The remote displaying apparatus according to claim 1, wherein the remote displaying apparatus is configured to connect with two or more image pickup apparatuses simultaneously and is configured to cause the image transmitted from one image pickup apparatus selected from the image pickup apparatuses to be displayed.
10. The remote displaying apparatus according to claim 1, wherein the main body further includes a sensor that senses an attitude of the remote displaying apparatus.
11. The remote displaying apparatus according to claim 1, wherein the main body further includes a sensor that senses an attitude of the remote displaying apparatus, and a direction in which the display is rotated based on a result of sensing by the sensor.
12. The remote displaying apparatus according to claim 1, wherein the main body further includes one or more side face operation sections.
13. The remote displaying apparatus according to claim 12, wherein the one or more side face operation sections are provided on one or more side faces along a first direction in which the display and a record operation button are arranged.
14. The remote displaying apparatus according to claim 13, wherein the side face operation sections are provided at positions not overlapping with each other along the first direction, when provided on opposite side faces respectively.
15. The remote displaying apparatus according to claim 1 further comprising:
a base plate configured to be interposed between the main body and the user arm when the remote displaying apparatus is worn on the user arm.